IL242760B - A Biomimetic Peptide and Biodegradable Delivery Platform for the Treatment of Angiogenesis and Lymphangiogenesis-Dependent Diseases - Google Patents

A Biomimetic Peptide and Biodegradable Delivery Platform for the Treatment of Angiogenesis and Lymphangiogenesis-Dependent Diseases

Info

Publication number
IL242760B
IL242760B IL242760A IL24276015A IL242760B IL 242760 B IL242760 B IL 242760B IL 242760 A IL242760 A IL 242760A IL 24276015 A IL24276015 A IL 24276015A IL 242760 B IL242760 B IL 242760B
Authority
IL
Israel
Prior art keywords
lymphangiogenesis
angiogenesis
treatment
delivery platform
dependent diseases
Prior art date
Application number
IL242760A
Other languages
English (en)
Hebrew (he)
Original Assignee
Univ Johns Hopkins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Johns Hopkins filed Critical Univ Johns Hopkins
Publication of IL242760B publication Critical patent/IL242760B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Zoology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
IL242760A 2013-06-07 2015-11-24 A Biomimetic Peptide and Biodegradable Delivery Platform for the Treatment of Angiogenesis and Lymphangiogenesis-Dependent Diseases IL242760B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361832290P 2013-06-07 2013-06-07
PCT/US2014/041526 WO2014197892A1 (en) 2013-06-07 2014-06-09 A biomimetic peptide and biodegradable delivery platform for the treatment of angiogenesis- and lymphangiogenesis-dependent diseases

Publications (1)

Publication Number Publication Date
IL242760B true IL242760B (en) 2021-03-25

Family

ID=52008639

Family Applications (1)

Application Number Title Priority Date Filing Date
IL242760A IL242760B (en) 2013-06-07 2015-11-24 A Biomimetic Peptide and Biodegradable Delivery Platform for the Treatment of Angiogenesis and Lymphangiogenesis-Dependent Diseases

Country Status (11)

Country Link
US (4) US9802984B2 (enExample)
EP (2) EP3643318A1 (enExample)
JP (2) JP6470740B2 (enExample)
CN (2) CN105431162B (enExample)
AU (1) AU2014274703B2 (enExample)
CA (1) CA2914764C (enExample)
DK (1) DK3003343T3 (enExample)
ES (1) ES2774217T3 (enExample)
HU (1) HUE047735T2 (enExample)
IL (1) IL242760B (enExample)
WO (1) WO2014197892A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6470740B2 (ja) * 2013-06-07 2019-02-13 ザ ジョンズ ホプキンス ユニバーシティ 血管新生およびリンパ管新生依存性疾患の処置のための生体模倣ペプチドおよび生分解性送達プラットフォーム
WO2016022947A1 (en) 2014-08-07 2016-02-11 The Johns Hopkins University Nanoparticle modification of human adipose-derived mesenchymal stem cells for treating brain cancer and other neurological diseases
KR101748120B1 (ko) * 2015-07-13 2017-06-16 서울대학교산학협력단 나노입자-유리체 기반 단백질 복합체를 유효성분으로 포함하는 혈관신생억제용 조성물 및 이의 용도
EP3377080B1 (en) 2015-11-19 2024-02-14 Asclepix Therapeutics, LLC Peptides with anti-angiogenic, anti-lymphangiogenic, and anti-edemic properties and nanoparticle formulations
WO2018067646A1 (en) * 2016-10-04 2018-04-12 Asclepix Therapeutics, Llc Compounds and methods for activating tie2 signaling
CA3063140A1 (en) * 2017-05-08 2018-11-15 Asclepix Therapeutics, Inc. Biodegradable microparticles for sustained delivery of anti-angiogenic peptide
US11674959B2 (en) 2017-08-03 2023-06-13 The Johns Hopkins University Methods for identifying and preparing pharmaceutical agents for activating Tie1 and/or Tie2 receptors
WO2019075056A1 (en) 2017-10-10 2019-04-18 The Johns Hopkins University BIODEGRADABLE BIOMIMETIC PARTICLES
US11697804B2 (en) 2018-10-01 2023-07-11 The Johns Hopkins University Transcriptionally targeted and CpG-free plasmid for theranostic gene therapy
WO2020163601A2 (en) * 2019-02-06 2020-08-13 The University Of North Carolina At Chapel Hill Compositions and methods for inhibiting post-surgical adhesions
CA3134816A1 (en) * 2019-03-26 2020-10-01 Asclepix Therapeutics, Inc. Compositions and methods for treating ocular disease
US12605463B2 (en) 2019-04-12 2026-04-21 The Johns Hopkins University Tolerogenic artificial antigen-presenting cells
CN113144213B (zh) * 2021-03-23 2023-04-07 西安交通大学医学院第一附属医院 一种多级pH响应基因-药物共递送的纳米药物、制备方法及其应用
WO2024044745A2 (en) * 2022-08-26 2024-02-29 Asclepix Therapeutics, Inc. Formulations for intraocular delivery of peptides derived from type iv collagen

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009512423A (ja) 2005-09-12 2009-03-26 ザ・ジョンズ・ホプキンス・ユニバーシティ 抗血管新生の活性を有する組成物及びその使用
WO2007120368A2 (en) * 2006-01-09 2007-10-25 The Regents Of The University Of California Immunostimulatory combinations for vaccine adjuvants
ITMI20060625A1 (it) * 2006-03-31 2007-10-01 Istituto Naz Per La Ricerca Peptide antiangiogenico e suoi impieghi terapeutici
CA2666709A1 (en) * 2006-11-10 2008-05-29 Genentech, Inc. Method for treating age-related macular degeneration
WO2008085828A2 (en) 2007-01-03 2008-07-17 The Johns Hopkins University Peptide modulators of angiogenesis and use thereof
WO2009135854A2 (en) * 2008-05-06 2009-11-12 Glaxo Group Limited Encapsulation of biologically active agents
JP2011528566A (ja) * 2008-07-21 2011-11-24 コンプジェン リミティッド アンジオポエチン由来ペプチド
WO2014066811A1 (en) 2012-10-25 2014-05-01 The Johns Hopkins University Bioreducible poly (b-amino ester)s for sirna delivery
US9717694B2 (en) * 2009-05-15 2017-08-01 The Johns Hopkins University Peptide/particle delivery systems
IN2012DN05099A (enExample) 2009-12-16 2015-10-09 Brigham & Womens Hospital
US20120192339A1 (en) 2010-07-28 2012-08-02 Honeywell International Inc. Flexible Body Armor Vest with Breast Plate
US20120270770A1 (en) * 2010-08-03 2012-10-25 Jesse Michael Jaynes Anti-angiogenic peptides and their uses
WO2012079088A2 (en) 2010-12-10 2012-06-14 The Johns Hopkins University Mimetic peptides derived from collagen type iv and their use for treating angiogenesis- and lymphangiogenesis- dependent diseases
JP5747312B2 (ja) 2011-02-24 2015-07-15 コニカミノルタ株式会社 活性光線硬化型インクジェットインク及び画像形成方法
US20150272900A1 (en) 2012-10-26 2015-10-01 The Johns Hopkins University Layer-By-Layer Approach to Co-Deliver DNA and siRNA via AuNPs: A Potential Platform for Modifying Release Kinetics
JP6470740B2 (ja) * 2013-06-07 2019-02-13 ザ ジョンズ ホプキンス ユニバーシティ 血管新生およびリンパ管新生依存性疾患の処置のための生体模倣ペプチドおよび生分解性送達プラットフォーム

Also Published As

Publication number Publication date
ES2774217T3 (es) 2020-07-17
DK3003343T3 (da) 2020-02-03
US10774112B2 (en) 2020-09-15
JP2016521712A (ja) 2016-07-25
CN105431162A (zh) 2016-03-23
CN105431162B (zh) 2019-12-10
WO2014197892A1 (en) 2014-12-11
JP6931011B2 (ja) 2021-09-01
EP3003343B1 (en) 2019-10-23
JP2019089790A (ja) 2019-06-13
US20200361993A1 (en) 2020-11-19
AU2014274703A1 (en) 2015-12-10
EP3003343A1 (en) 2016-04-13
HK1222542A1 (zh) 2017-07-07
US20180134753A1 (en) 2018-05-17
CA2914764A1 (en) 2014-12-11
US20160122390A1 (en) 2016-05-05
EP3643318A1 (en) 2020-04-29
AU2014274703B2 (en) 2019-07-04
CA2914764C (en) 2021-10-26
US11981754B2 (en) 2024-05-14
CN110981941A (zh) 2020-04-10
EP3003343A4 (en) 2016-11-30
US20240391957A1 (en) 2024-11-28
HUE047735T2 (hu) 2020-05-28
US9802984B2 (en) 2017-10-31
JP6470740B2 (ja) 2019-02-13

Similar Documents

Publication Publication Date Title
IL274646A (en) Integrated continuous production of medicinal substances from medical protein
IL285716A (en) Compacted molecules derived from colic toxin for oral delivery of a biologically active payload
IL250660A0 (en) Skin sensors for drug delivery devices
IL244259A0 (en) Insertion of medical devices
ZA201702634B (en) Therapeutic agent delivery device
IL241811B (en) A system for creating sprays that includes a source of compound that enhances delivery and a source of drug
IL247795B (en) tco couplings and methods for shipping medical materials
IL240849B (en) Drug delivery devices and drug delivery method
SG11201508180PA (en) Prosthetic heart valve delivery apparatus
SG11201609966SA (en) Drug delivery system and method of use
GB201515650D0 (en) Medicament delivery devices
IL245211A0 (en) an inhaler for the medicine
PL3234107T3 (pl) Limfocyty b do dostarczania in vivo środków terapeutycznych
EP3183026A4 (en) Implants for localized drug delivery and methods of use thereof
DK3003343T3 (da) Biomimetisk peptid og bionedbrydelig leveringsplatform til behandling af angiogenese- og lymfangiogeneseafhængige sygdomme
SG11201608483PA (en) Drug delivery systems and related methods of use
ZA201603117B (en) Withanolides useful for the treatment of neurodegenerative diseases
IL254625A0 (en) Device for targeted delivery of a therapeutic implant
IL248904A0 (en) Peptide-polypeptide composite nanoparticles for use in drug delivery
EP3136840A4 (en) Aided delivery of plant treatment agents
GB201511126D0 (en) Spray device for the delivery of therapeutic agents
GB201419540D0 (en) Delivery of drugs
GB201410507D0 (en) Drug delivery enhancement agents
GB201319437D0 (en) Delivery of drugs
GB201607794D0 (en) Medicament delivery devices

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed